TheraRadar
← Back
Data updated: Jun 28, 2026

US GENERICS, STERILES

Pharma
Pharmaceuticals

US GENERICS, STERILES is a pharmaceutical company with 1 FDA-approved products.

-
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Aug 13, 2026 — LNTH
Oct 17, 2026 — Phentolamine ophthalmic solution 0.75%

US GENERICS, STERILES's Key Drugs

US GENERICS, STERILES's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

US GENERICS, STERILES's Recent FDA Approvals

New NDA/BLA approvals for US GENERICS, STERILES over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

US GENERICS, STERILES's Therapeutic Areas

Disease areas where US GENERICS, STERILES has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

US GENERICS, STERILES Pipeline Snapshot

Active clinical trials for US GENERICS, STERILES across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling